Key facts
- This page summarizes Bethany Sensenig's Form 4 filing for SUPERNUS PHARMACEUTICALS, INC. (SUPN).
- 2 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 20 Feb 2026, 16:43.
Bethany Sensenig - 18 Feb 2026 Form 4 Insider Report for SUPERNUS PHARMACEUTICALS, INC. (SUPN)
- Reporting relationship
- Director
- Issuer ticker
- SUPN
- Reported as of
- 18 Feb 2026
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 20 Feb 2026, 16:43:00 UTC
- Prior SEC filing
- 02 Oct 2025
- Next SEC filing
- 23 Feb 2026
- Source filing
- View source filing
- Reporting owner signature
- /s/ Timothy C. Dec, as attorney-in-fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Bethany Sensenig filed Form 4 for SUPERNUS PHARMACEUTICALS, INC. (SUPN) on 20 Feb 2026.
Change
- Previous filing in this sequence was filed on 02 Oct 2025.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0001899935
Primary reporting owner
Sensenig Bethany
- Relationship
- Director
- Address
- C/O SUPERNUS PHARMACEUTICALS, INC., 9715 KEY WEST AVENUE, ROCKVILLE
- Signature
- /s/ Timothy C. Dec, as attorney-in-fact
- Signature date
- 20 Feb 2026
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
SUPN
transaction
Derivative
Restricted Stock Unit
Award
- Transaction value
- $0
- Shares
- +2,989
- Change %
- Price
- $0.000000
- Shares after
- 2,989
- Date
- 18 Feb 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 2,989
- Exercise price
- Footnotes
- F1, F2
SUPN
transaction
Derivative
Director Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +4,977
- Change %
- Price
- $0.000000
- Shares after
- 4,977
- Date
- 18 Feb 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 4,977
- Exercise price
- $50.20
- Footnotes
- F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
Each restricted stock unit represents the right to receive one share of Supernus common stock upon vesting.
Footnote F2
These restricted stock units will be settled in common stock upon vesting, which will occur on February 18, 2027.
Footnote F3
Each option vests on February 18, 2027.